Sentences with phrase «for metastatic lung cancer»

For example, Zykadia, a drug for metastatic lung cancer, received a «breakthrough therapy» designation that allows expedited approval based on preliminary evidence for certain drugs that treat serious conditions.

Researchers from the University of Portsmouth's Brain Tumour Research Centre of Excellence have identified molecules which are responsible for metastatic lung cancer cells binding to blood vessels in the brain.

Not exact matches

It has shown promise in metastatic melanoma, renal, and lung cancers — the last of which represents a huge opportunity for pharmaceutical companies (160,000 Americans are expected to die from lung cancer this year, compared with 10,000 from melanoma).

The abstract title was: Attempt to Validate Drug Repositioning for Metastatic Small Cell Lung Cancer (SCLC) Therapy Identifies Statins Associated with Survival Benefit.?

The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed.

Both drugs are approved for treating metastatic melanoma, and Opdivo is also approved for squamous lung cancer.

She expects she will find laminum - 8 uniquely overexpressed in other invasive cancers, like lung and colon cancer, but to date she has tested for it in only human brain and metastatic breast cancer.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

This will establish sequential crizotinib followed by a second generation ALK inhibitor as the standard treatment for patients with metastatic ALK positive lung cancer.»

Metastatic lung cancer developed in the proband's mother, and the radiographic appearance of the lung cancer was the same for both women, with bilateral ground - glass opacities and pulmonary nodules.

The therapy, reported in the Aug. 17 issue of Nature Communications, offers the hope of an effective treatment for intractable metastatic cancers including those of the colon and lung.

«Metastatic brain tumors — often from lung, breast or skin cancers — are the most commonly observed tumors within the brain and account for about 40 percent of advanced melanoma metastases.

«This technology [stereotactic body radiation] has been used successfully in both primary and metastatic lung and liver cancers, notably for patients who could not otherwise undergo surgery, with local control rates in excess of 90 percent» says Gan.

«Metastatic brain tumors — often from lung, breast or skin cancers — are the most commonly observed tumors within the brain and account for about 30 percent of advanced breast cancer metastases,» says Khalid Shah, MS, PhD, director of the Molecular Neurotherapy and Imaging Laboratory in the MGH Departments of Radiology and Neurology, who led the study.

The FDA granted approval to pembrolizumab (Keytruda), a anti-PD-1 checkpoint inhibitor, for metastatic non-small cell lung cancer patients whose tumors express PD - L1.

The FDA approved Opdivo ® (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) after prior therapy.

The FDA granted approval to atezolizumab (TECENTRIQ), and anti-PD-L1 checkpoint inhibitor, for patients with metastatic, chemotherapy - resistant non-small cell lung cancer (NSCLC).

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could aLung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.

April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.

Cancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develoCancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor development.

Clinical Trials Research and Billing First in Human / Early Phase PET in Oncology Case - Based Dose Reduction in Pediatric Nuclear Medicine: Practical and Necessary Radioiodine Therapy for Hyperthyroidism: The State of the Art Spondylodiscitis: Role of Imaging for Diagnosis and Monitoring Treatment Response Current Status and Future Prospects: PET and SPECT Instrumentation Alternative Payment Models and Value - Based Health Care: Nuts and Bolts Maximal Tolerated Activity of Radioactive Iodine for Metastatic Thyroid Cancer Teaching Old Radiopharmaceuticals New Tricks Intraoperative Detection Devices and Probes Molecular Imaging of Lung Inflammation Standardization of Advanced PET / SPECT Data Acquisition and Analysis Thyroid Cancer Management: Novel Therapeutics and Management Options Targeting Radionuclide Therapy in Various Non-Malignant Arthritic Conditions Using Radiosynoviorthesis (RSO) Are You Prepared for a Radiation Accident?

Merck's anti-PD-1 drug pembrolizumab (MK - 3475) is currently being investigated in a large a phase I trial for patients with metastatic melanoma and lung cancer.

This drug will be used for patients with metastatic or advanced lung cancer who did not respond to previous treatments.

Merck's cancer drug Keytruda got the nod of U.S. regulators as a first - line drug for treating metastatic non-small cell lung cancer.

In March, the U.S. Food and Drug Administration approved nivolumab for patients with advanced (metastatic) squamous non-small cell lung cancer.

These include imatinib, sold under the brand name Gleevec for chronic myeloid leukemia; gefitinib, sold as Iressa for metastatic non-small cell lung cancer; and sunitinib, marketed as Sutent, for renal cell cancer and gastrointestinal stromal tumors.

The FDA approved two anti-PD-1 antibodies (nivolumab / Bristol - Myers Squibb and pembrolizumab / Merck & Co.) for metastatic melanoma in 2014, and it extended approval to metastatic squamous non-small cell lung cancer earlier this year.

«He's been sick,» I said, because this had been going on for a year, and though nobody gets better from metastatic small - cell lung cancer, he'd been holding his own for months and months.

This drug is indicated in combination with Cisplatin (a chemotherapeutic drug) for the first - line treatment of patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.

Lameness for example occurs during the later stages of lung cancer, such as when the metastatic form of cancer spreads to the brain and bones.

It is currently approved for the treatment of a number of different cancers including metastatic colon cancer, and non-small cell lung cancer.